[1] Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. The Journal of bone and joint surgery American volume 1999;81:2-10. doi: 10.2106/00004623-199901000-00002.
[2] Callaghan JJ, O'Rourke MR, Liu SS. Blood management: issues and options. The Journal of arthroplasty 2005;20:51-4. doi: 10.1016/j.arth.2005.03.018.
[3] Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty?. Correct blood loss management should take hidden loss into account. The Knee 2000;7:151-55. doi: 10.1016/s0968-0160(00)00047-8.
[4] Grady-Benson JC, Oishi CS, Hanson PB, Colwell CW, Jr., Otis SM, Walker RH. Postoperative surveillance for deep venous thrombosis with duplex ultrasonography after total knee arthroplasty. The Journal of bone and joint surgery American volume 1994;76:1649-57. doi: 10.2106/00004623-199411000-00008.
[5] Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. The Journal of bone and joint surgery American volume 1984;66:194-201.
[6] Wang CJ, Wang JW, Weng LH, Hsu CC, Huang CC, Yu PC. Prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients. Comparison of low-molecular-weight heparin and indomethacin. The Journal of bone and joint surgery American volume 2004;86:136-40. doi: 10.2106/00004623-200401000-00020.
[7] Comadoll JL, Comadoll S, Hutchcraft A, Krishnan S, Farrell K, Kreuwel HT, Bechter M. Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKA. Orthopedics 2012;35:e785-93. doi: 10.3928/01477447-20120525-14.
[8] Grosu I, Lavand'homme P, Thienpont E. Pain after knee arthroplasty: an unresolved issue. Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA 2014;22:1744-58. doi: 10.1007/s00167-013-2750-2.
[9] Kim HJ, Fraser MR, Kahn B, Lyman S, Figgie MP. The efficacy of a thrombin-based hemostatic agent in unilateral total knee arthroplasty: a randomized controlled trial. The Journal of bone and joint surgery American volume 2012;94:1160-5. doi: 10.2106/JBJS.K.00531.
[10] Watts CD, Pagnano MW. Minimising blood loss and transfusion in contemporary hip and knee arthroplasty. The Journal of bone and joint surgery British volume 2012;94:8-10. doi: 10.1302/0301-620X.94B11.30618.
[11] Carson JL, Poses RM, Spence RK, Bonavita G. Severity of anaemia and operative mortality and morbidity. Lancet 1988;1:727-9. doi: 10.1016/s0140-6736(88)91536-x.
[12] Chang YL, Hung SH, Ling W, Lin HC, Li HC, Chung SD. Association between ischemic stroke and iron-deficiency anemia: a population-based study. PloS one 2013;8:e82952. doi: 10.1371/journal.pone.0082952.
[13] Pereira AA, Sarnak MJ. Anemia as a risk factor for cardiovascular disease. Kidney international Supplement 2003:S32-9. doi: 10.1046/j.1523-1755.64.s87.6.x.
[14] Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:287S-310S. doi: 10.1378/chest.126.3_suppl.287S.
[15] Shaieb MD, Watson BN, Atkinson RE. Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. The Journal of arthroplasty 1999;14:432-8. doi: 10.1016/s0883-5403(99)90098-0.
[16] Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. The Journal of bone and joint surgery British volume 1996;78:434-40.
[17] Georgiadis AG, Muh SJ, Silverton CD, Weir RM, Laker MW. A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty. The Journal of arthroplasty 2013;28:78-82. doi: 10.1016/j.arth.2013.03.038.
[18] Hiippala S, Strid L, Wennerstrand M, Arvela V, Mantyla S, Ylinen J, Niemela H. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. British journal of anaesthesia 1995;74:534-7. doi: 10.1093/bja/74.5.534.
[19] Ishida K, Tsumura N, Kitagawa A, Hamamura S, Fukuda K, Dogaki Y, Kubo S, Matsumoto T, Matsushita T, Chin T, Iguchi T, Kurosaka M, Kuroda R. Intra-articular injection of tranexamic acid reduces not only blood loss but also knee joint swelling after total knee arthroplasty. International orthopaedics 2011;35:1639-45. doi: 10.1007/s00264-010-1205-3.
[20] Panteli M, Papakostidis C, Dahabreh Z, Giannoudis PV. Topical tranexamic acid in total knee replacement: a systematic review and meta-analysis. The Knee 2013;20:300-9. doi: 10.1016/j.knee.2013.05.014.
[21] Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. The Journal of bone and joint surgery American volume 2010;92:2503-13. doi: 10.2106/JBJS.I.01518.
[22] Oz MC, Cosgrove DM, 3rd, Badduke BR, Hill JD, Flannery MR, Palumbo R, Topic N. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. The Fusion Matrix Study Group. The Annals of thoracic surgery 2000;69:1376-82. doi: 10.1016/s0003-4975(00)01194-2.
[23] Testini M, Marzaioli R, Lissidini G, Lippolis A, Logoluso F, Gurrado A, Lardo D, Poli E, Piccinni G. The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbeck's archives of surgery 2009;394:837-42. doi: 10.1007/s00423-009-0497-5.
[24] Renkens KL, Jr., Payner TD, Leipzig TJ, Feuer H, Morone MA, Koers JM, Lawson KJ, Lentz R, Shuey H, Jr., Conaway GL, Andersson GB, An HS, Hickey M, Rondinone JF, Shargill NS. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine 2001;26:1645-50. doi: 10.1097/00007632-200108010-00002.
[25] Di Francesco A, Flamini S, Fiori F, Mastri F. Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial. Indian journal of orthopaedics 2013;47:474-81. doi: 10.4103/0019-5413.118203.
[26] Helito CP, Gobbi RG, Castrillon LM, Hinkel BB, Pecora JR, Camanho GL. Comparison of Floseal(r) and electrocautery in hemostasis after total knee arthroplasty. Acta ortopedica brasileira 2013;21:320-2. doi: 10.1590/S1413-78522013000600004.
[27] Schwab PE, Thienpont E. Use of a haemostatic matrix does not reduce blood loss in minimally invasive total knee arthroplasty. Blood transfusion = Trasfusione del sangue 2015;13:435-41. doi: 10.2450/2015.0199-14.
[28] Suarez JC, Slotkin EM, Alvarez AM, Szubski CR, Barsoum WK, Patel PD. Prospective, randomized trial to evaluate efficacy of a thrombin-based hemostatic agent in total knee arthroplasty. The Journal of arthroplasty 2014;29:1950-5. doi: 10.1016/j.arth.2014.05.025.
[29] Yen SH, Lin PC, Chen B, Huang CC, Wang JW. Topical Tranexamic Acid Reduces Blood Loss in Minimally Invasive Total Knee Arthroplasty Receiving Rivaroxaban. BioMed research international 2017;2017:9105645. doi: 10.1155/2017/9105645.
[30] Owens WD, Felts JA, Spitznagel EL, Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology 1978;49:239-43. doi: 10.1097/00000542-197810000-00003.
[31] Haas SB, Cook S, Beksac B. Minimally invasive total knee replacement through a mini midvastus approach: a comparative study. Clinical orthopaedics and related research 2004:68-73. doi: 10.1097/01.blo.0000147649.82883.ca.
[32] Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery 1962;51:224-32.
[33] Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, Clement C, Robinson KS, Lewandowski B. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet 1997;350:1795-8. doi: 10.1016/S0140-6736(97)08140-3.
[34] Rabinov K, Paulin S. Roentgen diagnosis of venous thrombosis in the leg. Archives of surgery 1972;104:134-44. doi: 10.1001/archsurg.1972.04180020014004.
[35] Gazzeri R, Galarza M, Alfier A. Safety biocompatibility of gelatin hemostatic matrix (Floseal and Surgiflo) in neurosurgical procedures. Surgical technology international 2012;22:49-54.
[36] Aguilera X, Martinez-Zapata MJ, Bosch A, Urrutia G, Gonzalez JC, Jordan M, Gich I, Maymo RM, Martinez N, Monllau JC, Celaya F, Fernandez JA. Efficacy and safety of fibrin glue and tranexamic acid to prevent postoperative blood loss in total knee arthroplasty: a randomized controlled clinical trial. The Journal of bone and joint surgery American volume 2013;95:2001-7. doi: 10.2106/JBJS.L.01182.
[37] Schwab PE, Thienpont E. Use of a haemostatic matrix (Floseal(R)) does not reduce blood loss in minimally invasive total knee arthroplasty performed under continued aspirin. Blood transfusion = Trasfusione del sangue 2016;14:134-9. doi: 10.2450/2015.0023-15.
[38] Molloy DO, Archbold HA, Ogonda L, McConway J, Wilson RK, Beverland DE. Comparison of topical fibrin spray and tranexamic acid on blood loss after total knee replacement: a prospective, randomised controlled trial. The Journal of bone and joint surgery British volume 2007;89:306-9. doi: 10.1302/0301-620X.89B3.17565.
[39] Sabatini L, Trecci A, Imarisio D, Uslenghi MD, Bianco G, Scagnelli R. Fibrin tissue adhesive reduces postoperative blood loss in total knee arthroplasty. Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology 2012;13:145-51. doi: 10.1007/s10195-012-0198-7.